Cover Image
市場調查報告書

Agile Therapeutics, Inc. - 產品平台分析

Agile Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 259390
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Agile Therapeutics, Inc. - 產品平台分析 Agile Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 28 Pages
簡介

Agile Therapeutics, Inc.是基於其擁有的獨家專利經皮技術,來開發避孕用品的製藥公司,提供Progestin的避孕貼片。其貼片技術既穩定又可靠。一週僅需使用一次既便利又容易按時用藥。

本報告提供Agile Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Agile Therapeutics, Inc.的基本資料

Agile Therapeutics, Inc.概要

  • 主要資訊
  • 企業資料

Agile Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Agile Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Agile Therapeutics, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

Agile Therapeutics, Inc.:藥物簡介

  • (ethinyl estradiol + levonorgestrel)
  • AG-200 ER
  • levonorgestrel
  • AG-200 SP

Agile Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Agile Therapeutics, Inc.:最近的開發平台趨勢

Agile Therapeutics, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06886CDB

Summary

Global Markets Direct's, 'Agile Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Agile Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Agile Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Agile Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Agile Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Agile Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Agile Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Agile Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Agile Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Agile Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Agile Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Agile Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Agile Therapeutics, Inc. Snapshot
    • Agile Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Agile Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Agile Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Agile Therapeutics, Inc. - Pipeline Products Glance
    • Agile Therapeutics, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Agile Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Agile Therapeutics, Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Agile Therapeutics, Inc. - Drug Profiles
    • (ethinyl estradiol + levonorgestrel)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-200 ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levonorgestrel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-200 SP
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Agile Therapeutics, Inc. - Pipeline Analysis
    • Agile Therapeutics, Inc. - Pipeline Products by Target
    • Agile Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Agile Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Agile Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Agile Therapeutics, Inc. - Recent Pipeline Updates
  • Agile Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Agile Therapeutics, Inc., Key Information
  • Agile Therapeutics, Inc., Key Facts
  • Agile Therapeutics, Inc. - Pipeline by Indication, 2015
  • Agile Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Agile Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Agile Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Agile Therapeutics, Inc. - Phase III, 2015
  • Agile Therapeutics, Inc. - Phase II, 2015
  • Agile Therapeutics, Inc. - Phase I, 2015
  • Agile Therapeutics, Inc. - Discovery, 2015
  • Agile Therapeutics, Inc. - Pipeline by Target, 2015
  • Agile Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Agile Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Agile Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Agile Therapeutics, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Agile Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Agile Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Agile Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Agile Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Agile Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Agile Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top